Katie Peng Sells 5,446 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Katie Peng sold 5,446 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the completion of the transaction, the director owned 34,301 shares in the company, valued at approximately $1,848,137.88. This trade represents a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 2.2%

SRRK stock opened at $56.56 on Wednesday. The stock has a market capitalization of $6.78 billion, a PE ratio of -15.75 and a beta of 0.67. The company has a fifty day moving average of $48.79 and a 200-day moving average of $46.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $57.80.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period last year, the business posted ($0.67) EPS. As a group, analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Institutional Investors Weigh In On Scholar Rock

Institutional investors have recently modified their holdings of the company. Three Seasons Wealth LLC increased its stake in Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after purchasing an additional 222 shares in the last quarter. GAMMA Investing LLC boosted its position in Scholar Rock by 20.8% during the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after purchasing an additional 242 shares in the last quarter. Values First Advisors Inc. grew its holdings in Scholar Rock by 1.5% in the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock valued at $927,000 after purchasing an additional 286 shares during the last quarter. IFP Advisors Inc grew its holdings in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

SRRK has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Barclays upped their price objective on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. HC Wainwright increased their price objective on Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Finally, Wedbush boosted their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).